# NMN vs NR: Comparing NAD+ Precursors in the Research | NAD+

> NMN vs NR: two oral NAD+ precursors compared from the trial data — biochemical step to NAD+, route into the cell, and the size of the blood-NAD+ rise each produces.

Two oral precursors, set side by side under one light: how each becomes NAD+, and what the trials measured for each.

## The gist

NMN vs NR is a comparison of two **precursors** (building blocks the body converts into NAD+), not two drugs. Both are vitamin-B3-family molecules that cells turn into NAD+ (the energy-handling helper molecule), just by slightly different routes. NR is one step "earlier" and gets converted into NMN inside the cell; NMN is one step from NAD+ itself. This page reads what the human and animal studies measured for each, side by side — how much each raised blood NAD+ and how well each was tolerated. It reports findings only and recommends no product or dose.

## How each precursor becomes NAD+

The two molecules enter the salvage machinery at different points. Nicotinamide riboside (`NR-CAS 1341-23-7`) is phosphorylated to NMN by the NRK1/NRK2 kinases, a Preiss-Handler-independent route, and NMN is then converted to NAD+ by NMNAT [5]. Nicotinamide mononucleotide (`NMN-CAS 1094-61-7`) sits one biochemical step from NAD+, downstream of the rate-limiting salvage enzyme NAMPT [5]. In practice both reliably raise the NAD+ pool; the debate is about absorption, transport, and which gives the larger or more durable rise.

The human pharmacodynamic data are cleanest for NR. Across eight weeks, NR raised whole-blood NAD+ by 22%, 51%, and 142% at 100, 300, and 1000 mg/day, a clean dose-response with no flushing and no LDL elevation [4]. NMN's multicenter trial showed a dose-dependent blood-NAD+ rise at days 30 and 60 and named 600 mg/day optimal [3]. No head-to-head trial in this site's record crowns a winner on hard endpoints; both clear the first bar — they raise blood NAD+ — and the human outcome data beyond that remain limited for both [13].

## NAD+ vs NMN: Why Oral 'NAD+' Differs From a Precursor

A common confusion is treating oral "NAD+" and oral NMN as interchangeable. They are not. NAD+ itself is large, charged, and poorly taken up by cells intact, which is why most experts consider plain oral NAD+ capsules a weak strategy and precursors the rational one [6]. NMN, by contrast, is a defined precursor one step from NAD+ that cells readily assemble [5].

The practical upshot for reading studies: an oral-NMN or oral-NR trial is **not** a study of "taking NAD+," and the two should never be conflated. When this site reports that a trial "raised blood NAD+," the intervention was a precursor [3][4]. The only route that delivers NAD+ as such is infusion — and infused NAD+ is rapidly cleared from plasma and extensively metabolized extracellularly, a separate evidence base covered on the [research](/research) page.

## Is taking NAD orally effective?

Oral NAD+ itself is poorly absorbed intact, so the rational oral approach in the research is precursors [6]. Oral NMN and NR both raise blood NAD+ reliably and dose-dependently in randomized trials — NR by up to 142% at 1000 mg/day over eight weeks [4], NMN dose-dependently across 60 days [3]. Whether that blood-NAD+ rise translates to clinical benefit in humans is still being studied [13].

---

One cold light on the NAD+ record — the coenzyme's age-related dimming and the NMN and NR precursor trials read scene by scene and cited to source, with no clinic behind the frame and nothing here prescribed, dispensed, or sold.